Intracellularly Activatable Nanovasodilators To Enhance Passive Cancer Targeting Regime

• DOI: 10.1021/acs.nanolett.8b00495
• Publication Date: 2018-03-09T16:06:57Z
• Authors: V. G. Deepagan; Hyewon Ko; Seunglee Kwon; N. Vijayakameswar...; Sang Kyoon Kim; Wooram Um; Sohee Lee; Jiwoong Min; Jeongjin Lee; Ki Young Choi; Sol Shin; Minah Suh; Jae Hyung Park
• Keywords: 02 engineering and technology; 0210 nano-technology; 3. Good health

Conventional cancer targeting with nanoparticles has been based on the assumed enhanced permeability and retention (EPR) effect. The data obtained in clinical trials to date, however, have rarely supported presence of such an To address this challenge, we formulated intracellular nitric oxide-generating (NO-NPs) for tumor site-specific delivery NO, a well-known vasodilator, intention boosting EPR. These are self-assembled under aqueous conditions from amphiphilic copolymers poly(ethylene glycol) nitrated dextran, which possesses inherent NO release properties reductive environment cells. After systemic administration NO-NPs, quantitatively assessed visualized increased blood flow as well vascular than could be achieved without NO. Additionally, prepared doxorubicin (DOX)-encapsulated NO-NPs demonstrated consequential improvement therapeutic efficacy over control groups considerably improved DOX intratumoral accumulation. Overall, proof concept study implies high potency EPR enhancer achieve better outcomes.